Francesca Demichelis I TBC
- Speaker: Francesca Demichelis, Professor, Head of Computational and Functional Oncology Lab. University of Trento (Italy).
- Talk title: TBC
- Host: Joaquin Mateo
- Date & time: Friday 11st November, at 12:00 CET
- Auditorium of the Cellex Building
Dr. Demichelis has expertise in the area of cancer genomics that builds on more than ten years of interdisciplinary work with focus in the field of prostate cancer. Since 2011 she leads the Computational and Functional Oncology Laboratory (University of Trento) with 10 members (fully funded through competitive grants) including both computational and experimental wet laboratory post-docs and PhD students. Her research focuses on the characterization of cancer evolution and progression and on the identification of germline and somatic diagnostic and prognostic cancer biomarkers. The laboratory recently developed a framework to chart tumor evolution maps exploiting the clonality information of cell populations (Baca S et al, Cell 2013; Prandi D et al, Genome Biology 2014). Application to cell free DNA allowed to monitor lethal prostate cancer dynamics (Carreira S et al, Sci Transl Med. 2014 Sep 17;6(254):254ra125) and to study response to second-generation anti-AR treatment in castration resistant prostate cancer patients (Romanel A, et al. Sci Transl Med. 2015 Nov 4;7(312):312re10.). Her research group significantly contributed to the definition of the molecular determinants of AR-independent prostate cancer across genomics, transcriptomics and epigenetics and of treatment resistance mechanisms in collaboration with Weill Cornell Medicine (NY) and the Broad Institute of M.I.T. and Harvard University (Beltran H, Prandi D et al, Nat Med. 2016 Mar;22(3):298-305) and with Memorial Sloane Kettering (Mu P et al, Science 2017). Most recently she led a pioneering study that bridges the individual’s inherited genetics and acquired somatic genomics in the context of cancer development (Romanel A et al, Nat Communications, 2017). This study supports the need to characterize inherited determinants of molecularly defined subclasses of cancers.